To develop a broad range of anti-cancer therapies based on genetically engineered viruses and augmented by cancer specific immune factors or chemotherapeutic agents that can be delivered intratumorally or systemically.
Immvira was founded in Shenzhen China in May of 2015 by Prof. Bernard Roizman of University of Chicago and Prof. Grace Zhou formerly a Research Associate Professor at University of Chicago, Prof. Thomas Shenk of Princeton University, Prof. Richard Whitley of University of Alabama, Prof. Ralph Weichselbaum of University of Chicago.
Contributions by co-founders to the scientific background of Immvira
Grace Zhou Ph.D
Bernard Roizman Sc.D
Chair of BOD
Immvira Co., Limited was launched by US founders in Shenzhen China in May 2015. In September 2016, the company raised Round-A venture capital and is raising Round-A+ venture capital in the Fall of 2018. Immvira plans to initiate Phase 1 clinical trials in Australia in November 2018. Immvira plans to submit INDs in USA and China in November of 2019.
Immvira’s scientific objectives are based on numerous experimental designs of oHSV and outcomes of clinical trials. On the basis of extensive experience it is the intent of Immvira scientists to construct an oHSV that consists of 2 elements:
The first is a genetically engineered “backbone” virus consisting solely of viral genes. The backbone virus must be safe for administration by injection intratumorally or systemically to target tumors inaccessible by direct injection The backbone virus must be genetically stable. Moreover its genome must have space to allow insertion of additional non viral genes.
The second element consists of non viral genes inserted into the backbone virus to augment its potency as an anti-cancer agent. The genes inserted into the Immvira backbone virus have two objectives: to stimulate the immune system to target cancer cells as cells ‘foreign to the body and to insure that the unleashed immune therapies are not blocked by cancer cell defenses.
Immvira’s series T3 oHSV meet these objectives.
Innate immunity is frequently compromised In cancer cells. oHSV takes advantage of
differences in innate immune response. 0n injection into tumor mass it preferentially replicates in cancer
oHSV induces immunogenic cancer cell death to be recognized by immune system.
Cytokines released by infected cells induced an immune response to the uninfected tumor cells and destroyed them.
oHSV could be repeated many times without loss of Effectiveness.
In the course of tests conducted on a wide range of human tumors we have identified a small number of tumors that are resistant to our oHSV. Analyses of these tumors revealed that they share a common restrictive factor that blocks the oHSV from effectively expressing its genes. The number of resistant tumors analyzed to date is small and future studies may reveal additional restrictive factors. Current plan are to develop auxiliary immunotherapeutic molecules to be delivered to the tumors concurrently with the oHSV and which would render the tumors permissive.
Currently oHSV must be shipped from production to the operating table in containers maintaining the oHSV at -80℃. Immvira has developed protocols for oHSV storage in environments commonly found in hospital facilities.
What we offer:
Address:3F，Building 1-B, Silver Star Hi-tech Industrial Park, 1301 Guanguang Rd., Longhua District, Shenzhen, 518110, China